Literature DB >> 26450364

Survival after ultramassive transfusion: a review of 1360 cases.

Walter Sunny Dzik1, Alyssa Ziman2, Claudia Cohn3, Menaka Pai4, Miguel Lozano5, Richard M Kaufman6, Meghan Delaney7, Kathleen Selleng8, Michael F Murphy9, Tor Hervig10, Mark Yazer11.   

Abstract

BACKGROUND: Information about patient survival after transfusion of multiple blood volumes is limited, and most reports have focused on trauma patients. STUDY DESIGN AND METHODS: Retrospective study of blood use and survival at 11 hospitals in six nations between 2009 and 2013. Ultramassive transfusion (UMT) was defined as transfusion of 20 or more red blood cell (RBC) units over the course of any 2 consecutive calendar days.
RESULTS: A total of 1975 patients received UMT and a representative sample of 1360 patients was studied in detail. Patients were grouped into seven diagnostic categories: solid organ transplantation (n = 411), cardiac or major vascular surgery (n = 317), general surgery (n = 228), trauma (n = 221), general medicine (n = 124), obstetrics (n = 23), and other (n = 36). During the 7 days after initiation of UMT, these patients used more than 120,000 blood components. The median (interquartile range) blood use was 35 (26-50) RBC units, 30 (20-47) plasma units, and 7 (4-13) platelet doses. Five- and 30-day survival significantly declined with increasing RBC use. Overall survivals of patients receiving UMT were 71% (5 day) and 60% (30 day), and in the subset of 165 patients receiving 60 or more RBC units over 2 consecutive days, 5-day survival was 54% ranging from 17% (trauma) to 75% (solid organ transplant). The decline in survival with increasing RBC transfusions was minimal for patients undergoing solid organ transplantation and was most pronounced for trauma and nonsurgical bleeding patients.
CONCLUSION: Trauma was not the leading cause of UMT. Increasing RBC requirements were significantly associated with decreasing survival. However, survival was more strongly associated with diagnostic category than total RBCs transfused, with highest survival rates in solid organ transplant surgery.
© 2015 AABB.

Entities:  

Mesh:

Year:  2015        PMID: 26450364     DOI: 10.1111/trf.13370

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Association Between Ratio of Fresh Frozen Plasma to Red Blood Cells During Massive Transfusion and Survival Among Patients Without Traumatic Injury.

Authors:  Tomaz Mesar; Andreas Larentzakis; Walter Dzik; Yuchiao Chang; George Velmahos; Daniel Dante Yeh
Journal:  JAMA Surg       Date:  2017-06-01       Impact factor: 14.766

2.  Genetic testing to resolve the source of haemolytic antibody in solid organ transplantation.

Authors:  Hamilton C Tsang; Annie N Samraj; Ryan J Morse; Niklas Krumm; John R Hess; Monica B Pagano
Journal:  Blood Transfus       Date:  2019-06-05       Impact factor: 3.443

3.  Massive Transfusion in Cardiac Surgery: The Impact of Blood Component Ratios on Clinical Outcomes and Survival.

Authors:  Meghan Delaney; Paul C Stark; Minhyung Suh; Darrell J Triulzi; John R Hess; Marie E Steiner; Christopher P Stowell; Steven R Sloan
Journal:  Anesth Analg       Date:  2017-06       Impact factor: 5.108

4.  Improving outcomes for hospital patients with critical bleeding requiring massive transfusion: the Australian and New Zealand Massive Transfusion Registry study methodology.

Authors:  J C Oldroyd; K M Venardos; N J Aoki; A J Zatta; Z K McQuilten; L E Phillips; N Andrianopoulos; D J Cooper; P A Cameron; J P Isbister; E M Wood
Journal:  BMC Res Notes       Date:  2016-10-06

5.  Cost-effectiveness of point-of-care viscoelastic haemostatic assays in the management of bleeding during cardiac surgery: protocol for a prospective multicentre pragmatic study with stepped-wedge cluster randomised controlled design and 1-year follow-up (the IMOTEC study).

Authors:  Jean-Christophe Rigal; Elodie Boissier; Karim Lakhal; Valéry-Pierre Riche; Isabelle Durand-Zaleski; Bertrand Rozec
Journal:  BMJ Open       Date:  2019-11-05       Impact factor: 2.692

6.  Development and validation of a machine learning method to predict intraoperative red blood cell transfusions in cardiothoracic surgery.

Authors:  Zheng Wang; Shandian Zhe; Joshua Zimmerman; Candice Morrisey; Joseph E Tonna; Vikas Sharma; Ryan A Metcalf
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

7.  Outcomes after ultramassive transfusion in the modern era: An Eastern Association for the Surgery of Trauma multicenter study.

Authors:  Zachary A Matthay; Zane J Hellmann; Rachael A Callcut; Ellicott C Matthay; Brenda Nunez-Garcia; William Duong; Jeffry Nahmias; Aimee K LaRiccia; M Chance Spalding; Satya S Dalavayi; Jessica K Reynolds; Heather Lesch; Yee M Wong; Amanda M Chipman; Rosemary A Kozar; Liz Penaloza; Kaushik Mukherjee; Khaled Taghlabi; Christopher A Guidry; Sirivan S Seng; Asanthi Ratnasekera; Amirreza Motameni; Pascal Udekwu; Kathleen Madden; Sarah A Moore; Jordan Kirsch; Jesse Goddard; James Haan; Kelly Lightwine; Julianne B Ontengco; Daniel C Cullinane; Sarabeth A Spitzer; John C Kubasiak; Joshua Gish; Joshua P Hazelton; Alexandria Z Byskosh; Joseph A Posluszny; Erin E Ross; John J Park; Brittany Robinson; Mary Kathryn Abel; Alexander T Fields; Jonathan H Esensten; Ashok Nambiar; Joanne Moore; Claire Hardman; Pranaya Terse; Xian Luo-Owen; Anquonette Stiles; Brenden Pearce; Kimberly Tann; Khaled Abdul Jawad; Gabriel Ruiz; Lucy Z Kornblith
Journal:  J Trauma Acute Care Surg       Date:  2021-07-01       Impact factor: 3.697

8.  The value of institutional protocols and focused cardiac ultrasound during a case of ultramassive transfusion.

Authors:  Muhammad Salman Tahir Janjua; Shvetank Agarwal; Manuel R Castresana
Journal:  Ann Card Anaesth       Date:  2018 Oct-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.